The size of the preclinical in-vivo imaging market in the Middle East & Africa was estimated at USD 82.98 Million in 2022. It is projected to reach USD 109.02 Million by 2027, at a CAGR of 5.61% during the forecast period from 2022 to 2027.
Rising healthcare expenditure, increase in geriatric population, growing prevalence of cancer, and progress of R&D in imaging technologies for diagnosing various types of diseases such as cancer, are the major drivers for the MEA preclinical in-vivo imaging market growth. According to the WHO report, about 1 in 6 deaths occur due to cancer and its complications, making it the second leading cause of death globally. Approximately 70% of cancer deaths occur in low- and middle-income countries. In addition, the WHO states that around 17.95 million people die each year from cardiovascular diseases (CVD), which account for over 31% of total deaths globally.
The higher acceptance rate of multimodal in-vivo imaging systems in research studies and increased awareness of the early diagnosis of diseases are also analyzed to drive the growth of this market. Combining multiple imaging modalities in preclinical studies helps researchers understand molecular, cellular, and physiological changes in living animals and predict the outcomes of new treatments in patients. Pre-clinical in-vivo imaging is helping in drug discovery, cancer cell detection, and precision medication, supporting the market. In addition, preclinical in-vivo imaging is increasingly used in animal testing, compound optimization, and elaborate drug development.
Increased public and private sector funding have increased the adaptation of new technologies and acquisitions by different market players across the MEA region. For instance, the latest advancements in high-frequency ultrasound imaging used to detect early-stage cancer are analyzed to support high growth in the MEA preclinical in-vivo imaging market over the forecast period.
However, factors such as the strict regulatory framework governing preclinical research like the use of animals, etc., technological and procedural limitations associated with pre-clinical systems are some of the major factors restraining the growth of the MEA preclinical in-vivo imaging market. In addition, the excessive value of the product reduces adoption costs in academic institutions. High operational and maintenance costs restrain the market. Moreover, the adoption of many alternative methods and the development of computerized databases are growing rapidly, which may pose challenges for this studied market.
This research report on the MEA Preclinical In-Vivo Imaging Market is segmented and sub-segmented into the following categories:
Saudi Arabia is predicted to dominate the MEA preclinical in-vivo imaging market during the forecast period due to the region having developed infrastructure, many preclinical projects, large public and private companies, and higher adoption rates of technically advanced devices in this region. In addition, increasing funding for research and development coupled with a large number of research institutes is accelerating the growth of the market in Saudi Arabia.
Several factors, such as a robust R&D infrastructure for life science research, the rapid adoption of new molecular imaging technologies, the changing regulatory scenario, continued government support with funds and grants, the significant presence of pharmaceutical and biotech companies, and growing user preference for multimodal systems, are driving the growth of the preclinical in-vivo imaging market in the other MEA regions like United Arab Emirates, Qatar, Egypt, and South Africa.
KEY MARKET PLAYERS:
Companies playing an influential role in the MEA preclinical in-vivo imaging market profiled in this report are Aspect Imaging, Biospace Lab S.A., Bruker Corporation, LI-COR Biosciences, Mediso Ltd., MILabs B.V., MR Solutions Ltd, PerkinElmer, Inc., TriFoil Imaging and FUJIFILM VisualSonics, Inc.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]